| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-05-1571 |
| P698 | PubMed publication ID | 16397036 |
| P50 | author | Brian Schwartz | Q59594064 |
| P2093 | author name string | Chris H Takimoto | |
| Lillian L Siu | |||
| Malcolm J Moore | |||
| Martine Piccart | |||
| Ahmad Awada | |||
| Chetan Lathia | |||
| Oana Petrenciuc | |||
| Tom Giannaris | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| pancreatic cancer | Q212961 | ||
| P304 | page(s) | 144-151 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer | |
| P478 | volume | 12 |
| Q36892617 | A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia |
| Q42759889 | A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. |
| Q33404952 | A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study |
| Q37111209 | A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. |
| Q36593318 | A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 |
| Q33394594 | A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer |
| Q51065459 | A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. |
| Q28555059 | Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells |
| Q43158828 | Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q24234292 | Angiogenesis inhibitors for the treatment of ovarian cancer |
| Q24240350 | Angiogenesis-inhibitors for the treatment of ovarian cancer |
| Q37688711 | Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? |
| Q37832931 | Antiangiogenic therapies in epithelial ovarian cancer |
| Q38672966 | Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? |
| Q38151193 | Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer |
| Q37242685 | Biologic therapies for advanced pancreatic cancer |
| Q43077944 | Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact |
| Q43841175 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles |
| Q38553219 | Control of Apoptosis in Treatment and Biology of Pancreatic Cancer |
| Q37860976 | Defining new paradigms for the treatment of pancreatic cancer |
| Q35776091 | Developments in metastatic pancreatic cancer: is gemcitabine still the standard? |
| Q36610990 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. |
| Q35008709 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma |
| Q37588717 | Emerging Raf inhibitors. |
| Q37494647 | Emerging drugs in the treatment of pancreatic cancer |
| Q36744817 | Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. |
| Q34382777 | Exploiting novel molecular targets in gastrointestinal cancers. |
| Q33638830 | Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. |
| Q35057361 | Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium |
| Q39592955 | Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. |
| Q34005862 | Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer |
| Q36270115 | Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review |
| Q39132553 | Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells |
| Q48283864 | Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study |
| Q90231859 | Kinase Inhibitors and Ovarian Cancer |
| Q35297202 | Looking to the future: biomarkers in the management of pancreatic adenocarcinoma |
| Q37294511 | Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models |
| Q36944441 | Molecular targeted therapies for pancreatic cancer |
| Q37357949 | Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside |
| Q36582396 | Molecular therapies for malignant glioma |
| Q37355568 | Monoclonal antibodies in the treatment of pancreatic cancer. |
| Q46820301 | Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma |
| Q36974703 | New targets for non-small-cell lung cancer therapy |
| Q37345841 | New treatment options for advanced pancreatic cancer |
| Q38322346 | Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? |
| Q36623071 | Pancreatic cancer: a review of recent advances |
| Q33749460 | Pancreatic cancer: pathobiology, treatment options, and drug delivery |
| Q38552109 | Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. |
| Q35069647 | Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors |
| Q37188509 | Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. |
| Q34200743 | Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer |
| Q85026066 | Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer |
| Q35812808 | Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer |
| Q79396495 | Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma |
| Q33913549 | Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer |
| Q34504963 | Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. |
| Q37696502 | Safety profile of new anticancer drugs. |
| Q34280051 | Side effects of anti-angiogenic drugs |
| Q37307832 | Small molecule tyrosine kinase inhibitors in pancreatic cancer |
| Q34410212 | Smarter drugs emerging in pancreatic cancer therapy |
| Q36892799 | Sorafenib and sunitinib: novel targeted therapies for renal cell cancer |
| Q39725762 | Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. |
| Q38106994 | Sorafenib for ovarian cancer |
| Q42905241 | Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium |
| Q37243535 | Sorafenib in the treatment of advanced hepatocellular carcinoma |
| Q40286391 | Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant |
| Q84127318 | Sorafenib-associated multivessel coronary artery vasospasm |
| Q36872284 | Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors |
| Q33899923 | Targeted therapies for pancreatic cancer |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q37290448 | Targeted therapies in the management of metastatic bladder cancer |
| Q36040272 | Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook |
| Q35000785 | Targeting metastatic upper gastrointestinal adenocarcinomas |
| Q37082789 | Targeting signaling pathways in ovarian cancer. |
| Q38118388 | Targeting tyrosine-kinases in ovarian cancer |
| Q37676226 | Toxicity of sorafenib: clinical and molecular aspects |
| Q35750289 | Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies |
| Q61853685 | Vascular endothelial growth factor gene polymorphisms in ovarian cancer |
| Q36736364 | Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours |
| Q40083113 | What is the risk of intracranial bleeding during anti-VEGF therapy? |
Search more.